zl-n-91

ZL-N-91 is a **selective phosphodiesterase 4 (PDE4) inhibitor** in the **small molecule** class. It inhibits PDE4, thereby increasing intracellular cAMP levels, which aids in suppressing inflammatory and proliferative processes. Mechanistic studies indicate ZL-N-91 inhibits the proliferation of various cancer cell types (including glioblastoma, triple-negative breast cancer, and acute myeloid leukemia) by inducing G0/G1 cell cycle arrest, apoptosis, DNA damage response, and impairing mitochondrial function. In glioblastoma, ZL-N-91 acts through the EGR1/PTEN/AKT pathway, and in AML, it downregulates the Wnt/β-catenin signaling. Preclinical data show it is more potent than the reference PDE4 inhibitor rolipram in antitumor and anti-inflammatory activities. ZL-N-91 also demonstrates reduction of inflammatory responses in models of acute lung injury and COPD, supporting a broader therapeutic potential in inflammatory and respiratory diseases. It was developed by Zhejiang University.

Other names

zl-n-91zl-n91zl-n 91